Multiple Myeloma

Regional Health is involved in multiple myeloma research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.


PO-CL-MM-PI-003854
A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen

PURPOSE: The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM).

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Michael Robinson, MD
Medical Oncology

E1A11
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasome (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symotomatic Multiple Myeloma (ENDURANCE)

PURPOSE: This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone may kill more cancer cells

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Joshua Lukenbill, DO
Medical Oncology
Hematology

CTSU S1211
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma

PURPOSE: This phase I/II trial is studying the side effects and best dose of elotuzumab and to see how well it works when given with lenalidomide, bortezomib, and dexamethasone in treating patients with multiple myeloma.

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Joshua Lukenbill, DO
Medical Oncology
Hematology

CTSU E3A06
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

PURPOSE: This phase II/III trial is studying lenalidomide to see how well it works compared to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient.

To learn more, contact:
Regional Health
John T. Vucurevich Cancer Care Institute

(605) 755-2300

Principal Investigators
Joshua Lukenbill, DO
Medical Oncology
Hematology